Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

NCI Addresses Tobacco- Related Cancers in Women

March 1, 2005
By Roy S. Herbst, MD, PhD
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 14 No 3
Volume 14
Issue 3

This special “annual highlights” supplement to Oncology News International is acompilation of major advances in the management of lung cancer during 2004, asreported in ONI. Guest editor Dr. Roy Herbst discusses these advances in clinicalmanagement, with a focus on developments in adjuvant therapy for early disease,targeted therapy, and new chemotherapy findings.

BETHESDA, Maryland-Aworking group of the National CancerInstitute (NCI) has released a seriesof recommendations aimed atstimulating scientific research intotobacco-related cancers in women andtranslating discoveries into evidencebasedinterventions to prevent thecancers worldwide.The report, "Women, Tobacco,and Cancer: An Agenda for the 21stCentury," noted that the incidenceand mortality rates of smoking-relatedcancers in US women soared duringthe second half of the 20th century.Lung cancer mortality in womenincreased 600% between 1950 and1997, making it the leading cause ofcancer death in females.The NCI working group comprisedexperts from the institute, other federalagencies, nongovernment researchinstitutions, and advocacygroups. Members drew in part on informationcontained in several recentreports, including the 2001 SurgeonGeneral's report, "Women and Smoking,"which highlighted the importanceof gender-specific research intotobacco use and effects.The panel set several key goals forfuture research into tobacco-relatedcancers in women:

  • Increase our understanding ofsex differences across the broad rangeof research on women, tobacco, andcancer.
  • Develop new and more effectiveinterventions to prevent and treat tobaccouse and environmental tobaccosmoke exposure among womenand girls, especially in populations atgreatest risk; expand partnerships,networks, and innovative researchplatforms to ensure the widespreaddelivery of these interventions.
  • Improve national and globalevaluation and surveillance of thehealth hazards related to tobacco useand ETS exposure, specifically, ofwomen's and girls' knowledge, attitudes,and behaviors related to tobaccouse and associated risks.The working group emphasizedthat there is a critical need to betterunderstand sex differences as they relateto all phases of tobacco addictionand tobacco-related diseases."This includes genetic, molecular,cellular, neurobiological, biobehavioral,and hormonal factors thatplay a critical role in tobacco addictionand in the etiology of cancersand other diseases caused by tobacco,"the working group stated.Researchers also need to decipherthe etiologic role of gene-hormoneenvironmentinteractions in the cancers,and discover new methods forprevention and treatment of tobaccoaddiction. In addition, the NCI panelsaid that development of better treatmentand prevention techniques requiresidentifying the behavioral,psychosocial, sociocultural, and environmentalfactors that influence tobaccouse, exposure to second-handsmoke, and disease risk.

Translating basic and applied researchinto effective interventions willdepend on advances in four areas:

  • Using evidence from animalstudies, pilot projects, and small clinicaland community studies to developnew interventions for prevention,cessation, and treatment.
  • Finding ways to use or modifyexisting infrastructures to rapidly evaluatethe efficacy of promising treatmentsand the effectiveness and costefficiencyof proven small-scaleprograms and policies.
  • Exploring and strengthening thepositive health effects of tobacco-control policies on women and girls.
  • Monitoring the harmful effectsof tobacco marketing on females.

Delivering the proven results of researchand development efforts willdepend on finding ways to increasethe appeal, access, affordability, anduse of effective interventions, theworking group said. This, in turn, willrequire identifying and targeting messagesand strategies that successfullyinvolve individuals and organizationsin evidence-based tobacco-controlpolicies. Data from research-includingsurveillance, policy, economic,and cultural studies-need to be moreavailable to health care workers, policymakers, and the public, the paneladded.The NCI report also stressed theimportance of partnerships betweengovernment agencies, nongovernmentorganizations, private foundations,corporations, academic institutions,and community groups in acceleratingprogress in tobacco-related interventionsaimed at women and girls.Finally, the panel cited the importanceof local, national, and worldwideevaluation and surveillance indetermining the progress of efforts toreduce tobacco use, ETS exposure,and tobacco-related cancers amongwomen and girls, and to make changesin programs when needed.

Articles in this issue

Smoking Speeds Progression of Pancreas Ca
Alcohol, Obesity, and Smoking Risk Factors for HCC
Eloxatin Receives FDA Indication for Use in Adjuvant Treatment of Stage III Colon Cancer
Adding Bevacizumab Improves Response to Oxaliplatin Regimens
Capecitabine Promises Convenience, Efficacy in LARC, Five Studies Show
Avastin Enhances FOLFOX Efficacy
Panitumumab, Anti-EGFR MoAb,Promising in Colon Cancer
Oxaliplatin/Gemcitabine Effective in Advanced Pancreatic Cancer
Study Strengthens Evidence of Link Between Liver Cancer and Diabetes
Capecitabine Promises Convenience, Efficacy in LARC, Five Studies Show
Capecitabine Equal to Bolus 5-FU/LV in Adjuvant Therapy for Colon Cancer
Three Adjuvant 5-FU/RT Regimens Are Equally Effective
Single-Agent Cetuximab Active in Patients With Refractory Colon Cancer
XELIRI Shows Promise as First-Line Treatment for Advanced Colorectal Ca
UFT Provides ‘Equivalent’ Survival and Quality of Life to 5-FU in Stage II/III Colorectal Cancer
Recent Videos
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
In a CancerNetwork® YouTube video, Cornelia Tischmacher, a mother of twins from Germany, outlined her receipt of double lung transplantation.
Related Content
Advertisement

The blood-based test detected 31% of lung cancers 1 year prior to in-trial diagnosis compared with 8% of cancers identified by low-dose CT or Lung-RADS.

Blood-Based Screening Test May Increase Preclinical Lung Cancer Detection

Roman Fabbricatore
November 22nd 2025
Article

The blood-based test detected 31% of lung cancers 1 year prior to in-trial diagnosis compared with 8% of cancers identified by low-dose CT or Lung-RADS.


Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.


One patient with metastatic bladder cancer experienced an ongoing metabolic complete response following treatment with aldesleukin/imneskibart.

Imneskibart Yields Activity and Responses in Melanoma, NSCLC Cohorts

Russ Conroy
November 11th 2025
Article

One patient with metastatic bladder cancer experienced an ongoing metabolic complete response following treatment with aldesleukin/imneskibart.


Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc
September 16th 2024
Podcast

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.


How Dato-DXd and the TROPION Trials Are Transforming Solid Tumor Research

How Dato-DXd and the TROPION Trials Are Transforming Solid Tumor Research

Ariana Pelosci
November 8th 2025
Article

Dato-DXd is being assessed in numerous trials across the breast, lung, and bladder cancer spaces.


ILKN421H plus pembrolizumab previously showed antitumor activity among patients with frontline non–small cell lung cancer in a phase 1 trial.

FDA Clears IND Application for Novel IL-2 Agent in Advanced NSCLC

Russ Conroy
November 4th 2025
Article

ILKN421H plus pembrolizumab previously showed antitumor activity among patients with frontline non–small cell lung cancer in a phase 1 trial.

Related Content
Advertisement

The blood-based test detected 31% of lung cancers 1 year prior to in-trial diagnosis compared with 8% of cancers identified by low-dose CT or Lung-RADS.

Blood-Based Screening Test May Increase Preclinical Lung Cancer Detection

Roman Fabbricatore
November 22nd 2025
Article

The blood-based test detected 31% of lung cancers 1 year prior to in-trial diagnosis compared with 8% of cancers identified by low-dose CT or Lung-RADS.


Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.


One patient with metastatic bladder cancer experienced an ongoing metabolic complete response following treatment with aldesleukin/imneskibart.

Imneskibart Yields Activity and Responses in Melanoma, NSCLC Cohorts

Russ Conroy
November 11th 2025
Article

One patient with metastatic bladder cancer experienced an ongoing metabolic complete response following treatment with aldesleukin/imneskibart.


Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc
September 16th 2024
Podcast

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.


How Dato-DXd and the TROPION Trials Are Transforming Solid Tumor Research

How Dato-DXd and the TROPION Trials Are Transforming Solid Tumor Research

Ariana Pelosci
November 8th 2025
Article

Dato-DXd is being assessed in numerous trials across the breast, lung, and bladder cancer spaces.


ILKN421H plus pembrolizumab previously showed antitumor activity among patients with frontline non–small cell lung cancer in a phase 1 trial.

FDA Clears IND Application for Novel IL-2 Agent in Advanced NSCLC

Russ Conroy
November 4th 2025
Article

ILKN421H plus pembrolizumab previously showed antitumor activity among patients with frontline non–small cell lung cancer in a phase 1 trial.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.